OmniAb (OABI) Retained Earnings (2021 - 2026)
OmniAb (OABI) reported Retained Earnings of -$2000.0 for Q1 2026, down 125.0% year-over-year from $8000.0 in Q1 2025, and up 100.0% on a QoQ basis from -$166.2 million in Q4 2025.
OmniAb (OABI) has 6 years of Retained Earnings data on file, last reported at -$2000.0 in Q1 2026.
- Quarterly Retained Earnings fell 125.0% year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2000.0 (down 125.0% YoY) and the FY2025 annual result came in at -$166.2 million, down 615577.78% from the prior year.
- Retained Earnings improved to -$2000.0 in Q1 2026 per OABI's latest filing, from -$166.2 million in the prior quarter.
- Across five years, Retained Earnings topped out at $5.2 million in Q1 2023 and bottomed at -$166.2 million in Q4 2025.
- The 5-year median for Retained Earnings is -$13.9 million (2022), against an average of -$36.5 million.
- The widest annual swing landed in 2023, when Retained Earnings jumped 141.67%; it then tumbled 615577.78% in 2025.
- Tracing OABI's Retained Earnings over 5 years: stood at $9000.0 in 2022, then tumbled by 437511.11% to -$39.4 million in 2023, then surged by 100.07% to $27000.0 in 2024, then plunged by 615577.78% to -$166.2 million in 2025, then jumped by 100.0% to -$2000.0 in 2026.
- Per Business Quant, the three latest OABI Retained Earnings figures stand at -$2000.0 (Q1 2026), -$166.2 million (Q4 2025), and $5000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | -2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,000.00 |
| Dec 31, 2025 | -166.18 Mn |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | -135.48 Mn |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | -88.33 Mn |
| Jun 30, 2024 | -71.96 Mn |
| Mar 31, 2024 | -58.33 Mn |
| Dec 31, 2023 | -39.37 Mn |
| Sep 30, 2023 | -25.31 Mn |
| Jun 30, 2023 | -49,000.00 |
| Mar 31, 2023 | 5.15 Mn |
| Dec 31, 2022 | 9,000.00 |
| Sep 30, 2022 | -13.87 Mn |
| Jun 30, 2022 | -14.34 Mn |
| Mar 31, 2022 | -12.36 Mn |
| Sep 30, 2021 | -6.90 Mn |
| Jun 30, 2021 | -9,971.00 |